


Diastereodivergent Chiral Synthesis of the Furofuran Lignans (+)-Sesamin and (-)-Asarinin

Kiyohiro Samizu and Kunio Ogasawara*
Pharmaceutical Institute, Tohoku University, Aobayama, Sendai 980-77


(Received March 30, 1995)

Two diastereomeric lignans (+)-sesamin and (-)-asarinin have been prepared diastereodivergently *via* the common intermediate generated by the chirotopical Heck reaction.

Quite recently, we have developed an efficient route to both enantiomeric 1,2-butyndiol (**1**) from *meso*-3,4-epoxy-2,5-dihydrofuran.¹ To exploit **1** as a chiral building block, we used (*R*)-**1** for the diastereodivergent construction of two typical diastereomeric furofuran lignans, (+)-sesamin^{2,3} (**2**) and (-)-asarinin^{2,3} (**3**) based on the racemic approach we have established⁴ (Scheme 1).



Scheme 1.



Scheme 2. Reagent and conditions: i) cyclohexanone, *p*-TsOH (cat.) (98%). ii) *n*-BuLi, I₂, THF, -78 °C (99%). iii) (NCO₂K)₂, AcOH, MeOH, rt (76%). iv) 1) *n*-Bu₃SnH, xylene (37%), 2) I₂, CH₂Cl₂, -78 °C (73%).

We first transformed⁵ (*R*)-**1** (>99% ee) into the *Z*-iodoolefin **Z-6**, [α]_D²⁶ +17.1° (*c* 0.73, CHCl₃), by sequential ketalization, iodination and the diimide reduction⁵ *via* **4**, [α]_D³¹ -43.5° (*c* 1.13, CHCl₃), and **5**, [α]_D³⁰ -37.5° (*c* 1.08, CHCl₃).

On the other hand, (*R*)-**1** was transformed into the *E*-iodoolefin **E-6**, [α]_D²⁷ -38.3° (*c* 0.99, CHCl₃) on sequential treatment of **4** with tri-*n*-butyltin hydride and iodine⁶ (Scheme 2).


The Heck reaction⁴ between **Z-6** and the dioxepin **7** was next carried out to give **8** as an inseparable mixture consisted of a pair of the *E*-olefinic and a pair of the *Z*-olefinic diastereomers in ~4:1 ratio both having 2,5-*trans* configuration.⁷ ¹H NMR revealed the former to be ~4:1 and the latter to be ~1:1 mixtures of the diastereomers.⁷ The mixture was then treated with Ti(OPrⁱ)₂Cl₂⁴ followed by sodium borohydride (NBH) to give the diastereomeric *E*-olefinic **11E** (~4:1)⁷ and the diastereomeric *Z*-olefinic **11Z** (~1:1)⁷ mixtures of the 2,3-*trans*:3,4-*cis*-tetrahydrofurans⁸ in yields of 51 and 12%, *via* **10**, both preserving the original *E/Z*- and diastereomeric ratios.

When the same product was exposed to TBSOTf⁴ followed by NBH, the *E*-olefinic **14E** (~4:1)⁷ and the *Z*-olefinic **14Z** (~1:1)⁷ mixture were obtained in yields of 35 and 9%, *via* **13**, both preserving the original *E/Z*- and diastereomeric ratios.


On the other hand, the Heck reaction between **E-6** and **7** afforded a complex mixture consisted mostly of the *E*-olefinic 2,5-*trans/cis*-mixture (1:1) accompanied by the separable *Z*-olefinic products⁷ (*E/Z*=12:1). The *E*-mixture furnished either the 2,3-*trans*:3,4-*cis*-**11E** by Ti(OPrⁱ)₂Cl₂-NBH or the 2,3-*cis*:3,4-*trans*-**14E** by TBSOTf-NBH as above in comparable yields, but both as 1:1 diastereomeric mixtures.

The diastereoselective formation of the trisubstituted tetrahydrofurans **10** and **13** from the common oxepin **8** depending on the acid catalysts may be rationalized in terms of an intervention of the metal chelating complex **9** in the former and the non-chelating complex **12** in the latter⁴ (Scheme 3).


We next transformed **11** and **14** into the natural lignans sesamin (**2**) and asarinin (**3**), respectively. Very surprisingly, only the *E*-isomers generated from **Z-6** furnished the optically active products. Thus, **11E** furnished (+)-samin^{9,10} [(+)-**16**], [α]_D²⁷ +57.1° (*c* 0.37, CHCl₃) (lit.⁹: [α]_D²⁴ -88.18° (*c* 1.1, CHCl₃) for *ent*-**16**),¹¹ in 62% ee in 75% yield, *via* **15** on sequential dihydroxylation and periodate cleavage, while **11Z** gave the optically inactive **16**. Since optically pure (-)-samin



Scheme 3. Reagents and conditions: i) Pd₂(dba)₃·CHCl₃ (cat.), *o*-tol₃P (cat.), K₂CO₃ (2 equiv.), DMF, 40 °C, 1 h then 65 °C, 10 h.



Scheme 4. Reagents and conditions: i) OsO_4 (cat.), NMO, aq. THF, 45°C , then NaIO_4 , aq. THF, rt (**16**, 75%). ii) MeONa, MeOH, rt (**19**, 64%, 2 steps). iii) 1) TBS-Cl, imidazole, DMF, rt, 16h, 2) TMS-Br, CH_2Cl_2 , -78°C , then ArMgBr (66%, 2 steps).



Scheme 5.

[(-)-**16**] has been transformed into (-)-sesamin (*ent*-**2**) without loss of the original chiral integrity,⁹ the present synthesis constitutes a formal acquisition of (+)-sesamin (**2**) in 62% ee.

Similarly, only **14E** from **Z-6** furnished optically active (-)-**19**,¹⁰ $[\alpha]_{\text{D}}^{26} -74.9^\circ$ (*c* 0.19, CHCl_3), in 61% ee in 64% yield via **17** and **18** on sequential dihydroxylation, periodate cleavage, and base-induced isomerization.^{4b} By following the racemic synthesis, (-)-**19** was transformed to (-)-asarinin (**3**), $[\alpha]_{\text{D}}^{26} -71.9^\circ$ (*c* 0.19, CHCl_3) (lit.¹²: $[\alpha]_{\text{D}} +124^\circ$ (CHCl_3 for *ent*-**3**¹¹)) (61% ee), in 66% yield (Scheme 4). The optical purities obtained corresponded to the diastereomeric ratio (~4:1) of the starting **11E** generated from **Z-6**. It should be also noted that **11E** generated from **E-6** also furnished **16** and **19**, on the same treatments, which, however, did not have optical activities.

The chirality transfer exerted only by **Z-6** may be due to the intervention of the chelation complex **20** having the palladadihydrofuran moiety.¹³ This collapsed to **Z-21** which in turn isomerized to **E-23** through **22a** and its less congested conformer **22b** to leave the optically active **8E** by β -elimination.¹³ A similar reaction involving the palladadihydropyran may also occur competitively leading to a diastereomeric product (enantiomeric at the oxepin ring of **8**) which offset total optical transfer rate. The low chirality transfer in the **Z**-olefin product may be due to the competitive direct β -elimination in **21** and in the palladadihydropyran to give a 1:1 diastereomeric mixture incidentally. Since **E-6** was unable to

form a palladacyclic complex, no chiral induction occurred under the same conditions (Scheme 5).

References and Notes

- O. Yamada and K. Ogasawara, *Synlett*, **1995**, 427.
- For reviews of lignan chemistry: D. A. Whiting, *Nat. Prod. Rep.*, **12**, 183 (1995) and the earlier reviews.
- For a monograph of lignans: D. C. Ayres and J. D. Loike, 'Lignans Chemical Biological and Clinical Properties,' Cambridge University Press, Cambridge (1990).
- a) S. Takano, K. Samizu, and K. Ogasawara, *J. Chem. Soc., Chem. Commun.*, **1993**, 1032. b) S. Takano, K. Samizu, and K. Ogasawara, *Synlett*, **1993**, 785.
- D. J. Pasto and R. T. Taylor, *Org. React.*, **40**, 92 (1991).
- G. A. Tolstikov, M. S. Miftakhov, N. A. Danilova, and Y. L. Vel'der, *Synthesis*, **1986**, 496.
- Determined by ^1H NMR (500 MHz) analysis (NOE).
- Each compound contained ca. 4% of a diastereomer.
- S. Takano, T. Ohkawa, S. Tamori, S. Satoh, and K. Ogasawara, *J. Chem. Soc., Chem. Commun.*, **1988**, 189.
- Existed in a single isomer as shown in Scheme 4.⁷
- Both enantiomers are naturally occurring.
- K. Freudenberg and G. Sidhu, *Chem. Ber.*, **94**, 851 (1961).
- Torii, H. Okumoto, H. Ozaki, S. Nakayasu, T. Tadokoro, and T. Kotani, *Tetrahedron Lett.*, **33**, 3499 (1992).